首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1578296

全球自體細胞治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Autologous Cell Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年09月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球自體細胞治療市場需求預計將從 2023 年的 48.6 億美元達到近 307.1 億美元的市場規模，2024-2032 年研究期間複合年成長率為 22.74%。

自體細胞療法（ACT）是一種利用個別細胞治療各種疾病的新型療法。此療法利用在體外培養的患者細胞，細胞數量在體外擴增並重新引入體內。此療法可確保減少副作用，降低生物不相容性、與移植物相關的疾病傳播以及全身免疫反應和疾病的風險。治療可以有兩種類型：自體幹細胞療法和自體細胞免疫療法。來自骨髓表皮或其他來源的細胞用於細胞培養和擴增。自體療法用於治療癌症、肌肉骨骼疾病、血液疾病和美容治療。醫院和研究中心正在增加使用自體療法來治療患者。

市場動態

癌症、神經系統疾病和自體免疫疾病的日益普及是推動自體治療市場的主要因素。副作用減少和其他疾病傳播風險降低等因素正在推動市場發展。此外，細胞培養研發的增加以及政府在新型創新療法方面的措施正在提振全球市場。在全球COVID-19大流行期間，由於整體醫療保健市場的成長以及細胞培養療法研發的不斷增加，自體治療市場預計將經歷穩定但傾斜的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球自體細胞治療市場的各個細分市場進行了包容性評估。自體細胞治療產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

自體細胞治療市場報告的這一部分提供了國家和地區層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按申請

癌症
神經退化性疾病
心血管疾病
自體免疫疾病
骨科
傷口癒合
其他

按來源

骨髓
表皮
間質幹細胞
造血幹細胞
軟骨細胞
其他

按最終用途

醫院和診所
門診中心
學術與研究
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲自體細胞治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。自體細胞治療市場的主要參與者包括 BrainStorm Cell Therapeutics、Holostem Terapie Avanzate、SRL、Pharmicell Co. Inc、Opexa Therapeutics、Caladrius Biosciences Inc、US Stem Cell Inc、Lonza、Bristol Myers Squibb、諾華、Autoego Therapeutics、T Science 、康寧公司、Bio Elpida、Vericel Corporation、Catalent Inc、Sartorius AG。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：自體細胞治療公司的競爭格局

自體細胞治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
BrainStorm Cell Therapeutics

公司概況
公司收入
產品
最新動態

Holostem Terapie Avanzate SRL

公司概況
公司收入
產品
最新動態

Sartorius AG

公司概況
公司收入
產品
最新動態

Pharmicell Co. Inc

公司概況
公司收入
產品
最新動態

Opexa Therapeutics

公司概況
公司收入
產品
最新動態

Caladrius Biosciences Inc

公司概況
公司收入
產品
最新動態

US Stem Cell Inc

公司概況
公司收入
產品
最新動態

Lonza

公司概況
公司收入
產品
最新動態

Bristol Myers Squibb

公司概況
公司收入
產品
最新動態

Novartis

公司概況
公司收入
產品
最新動態

Autolus Therapeutics

公司概況
公司收入
產品
最新動態

Tego Science

公司概況
公司收入
產品
最新動態

Corning Incorporated

公司概況
公司收入
產品
最新動態

Bio Elpida

公司概況
公司收入
產品
最新動態

Vericel Corporation

公司概況
公司收入
產品
最新動態

Catalent Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11212590

The global demand for Autologous Cell Therapy Market is presumed to reach the market size of nearly USD 30.71 Billion by 2032 from USD 4.86 Billion in 2023 with a CAGR of 22.74% under the study period 2024-2032.

Autologous cell therapy (ACT) is a novel therapy that uses an individual's cells to treat various diseases. The therapy utilizes the patient's cells, which are cultured outside the body, the cell number is expanded in-vitro and reintroduced to the body. The therapy assures reduced side effects, reduced the risk of bio-incompatibility, disease transmission associated with graft, and systemic immunological reactions and disease. The therapy can be of two types; autologous stem cell therapy and autologous cellular immune therapies. The cells from bone marrow epidermis or other sources are utilized for cell culture and expansion. Autologous therapy is applied in the treatment of cancers, musculoskeletal disorders, blood disorders, and cosmetic treatments. Hospitals and research centers are increasing the use of autologous therapy to treat patients.

MARKET DYNAMICS

The growing prevalence of cancer, neurological disorders, and autoimmune diseases are the prime factors that are driving the autologous therapy market. The factors such as reduced side effects and reduced risk of transmission of other diseases are fuelling the market. Moreover, increasing R & D in cell culture, and government initiatives in novel innovative therapies is uplifting the global market. During the global pandemic COVID-19, the autologous therapy market is expected to experience steady but inclining growth owing to the growing overall healthcare market along with rising R & D in cell culture therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Autologous Cell Therapy. The growth and trends of Autologous Cell Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Autologous Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Cancer
Neurodegenerative Disorders
Cardiovascular Disorders
Autoimmune Disorders
Orthopedics
Wound Healing
Others

By Source

Bone Marrow
Epidermis
Mesenchymal Stem Cells
Haematopoietic Stem Cells
Chondrocytes
Others

By End-use

Hospitals & Clinics
Ambulatory Centers
Academics & Research
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Autologous Cell Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Autologous Cell Therapy market include BrainStorm Cell Therapeutics, Holostem Terapie Avanzate, S.R.L, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Autolus Therapeutics, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent Inc, Sartorius AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. AUTOLOGOUS CELL THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Source
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Cancer Historic and Forecast Sales By Regions
5.4. Neurodegenerative Disorders Historic and Forecast Sales By Regions
5.5. Cardiovascular Disorders Historic and Forecast Sales By Regions
5.6. Autoimmune Disorders Historic and Forecast Sales By Regions
5.7. Orthopedics Historic and Forecast Sales By Regions
5.8. Wound Healing Historic and Forecast Sales By Regions
5.9. Others Historic and Forecast Sales By Regions

6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY SOURCE

6.1. Overview By Source
6.2. Historical and Forecast Data Analysis By Source
6.3. Bone Marrow Historic and Forecast Sales By Regions
6.4. Epidermis Historic and Forecast Sales By Regions
6.5. Mesenchymal Stem Cells Historic and Forecast Sales By Regions
6.6. Haematopoietic Stem Cells Historic and Forecast Sales By Regions
6.7. Chondrocytes Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Hospitals & Clinics Historic and Forecast Sales By Regions
7.4. Ambulatory Centers Historic and Forecast Sales By Regions
7.5. Academics & Research Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE AUTOLOGOUS CELL THERAPY COMPANIES

9.1. Autologous Cell Therapy Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF AUTOLOGOUS CELL THERAPY INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. BrainStorm Cell Therapeutics
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Holostem Terapie Avanzate S.R.L
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Sartorius AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Pharmicell Co. Inc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Opexa Therapeutics
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Caladrius Biosciences Inc
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. U.S. Stem Cell Inc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Lonza
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Bristol Myers Squibb
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Novartis
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Autolus Therapeutics
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Tego Science
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Corning Incorporated
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. Bio Elpida
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Vericel Corporation
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Catalent Inc
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments